Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 332
Filtrer
1.
Pediatr Blood Cancer ; 71(7): e31017, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38706206

RÉSUMÉ

BACKGROUND: National sickle cell disease (SCD) guidelines recommend oral hydroxyurea (HU) starting at 9 months of age, and annual transcranial Doppler (TCD) screenings to identify stroke risk in children aged 2-16 years. We examined prevalence and proportion of TCD screenings in North Carolina Medicaid enrollees to identify associations with sociodemographic factors and HU adherence over 3 years. STUDY DESIGN: We conducted a longitudinal study with children ages 2-16 years with SCD enrolled in NC Medicaid from years 2016-2019. Prevalence of TCD screening claims was calculated for 3 years, and proportion was calculated for 12, 24, and 36 months of Medicaid enrollment. Enrollee HU adherence was categorized using HU proportion of days covered. Multivariable Poisson regression assessed for TCD screening rates by HU adherence, controlling for age, sex, and rurality. RESULTS: The prevalence of annual TCD screening was between 39.5% and 40.1%. Of those with 12-month enrollment, 77.8% had no TCD claims, compared to 22.2% who had one or higher TCD claims. Inversely, in children with 36 months of enrollment, 36.7% had no TCD claims compared to 63.3% who had one or higher TCD claims. The proportion of children with two or higher TCD claims increased with longer enrollment (10.5% at 12 months, 33.7% at 24 months, and 52.6% at 36 months). Children with good HU adherence were 2.48 (p < .0001) times more likely to have TCD claims than children with poor HU adherence. CONCLUSION: While overall TCD screening prevalence was low, children with better HU adherence and longer Medicaid enrollment had more TCD screenings. Multilevel interventions are needed to engage healthcare providers and families to improve both evidence-based care and annual TCD screenings in children with SCD.


Sujet(s)
Drépanocytose , Antidrépanocytaires , Hydroxy-urée , Échographie-doppler transcrânienne , Humains , Drépanocytose/traitement médicamenteux , Drépanocytose/épidémiologie , Drépanocytose/imagerie diagnostique , Enfant , Hydroxy-urée/usage thérapeutique , Femelle , Mâle , Adolescent , Enfant d'âge préscolaire , Études longitudinales , Antidrépanocytaires/usage thérapeutique , Medicaid (USA)/statistiques et données numériques , Adhésion au traitement médicamenteux/statistiques et données numériques , Accident vasculaire cérébral/épidémiologie , Accident vasculaire cérébral/prévention et contrôle , États-Unis/épidémiologie , Études de suivi , Caroline du Nord/épidémiologie , Pronostic
2.
J Hosp Infect ; 117: 89-95, 2021 Nov.
Article de Anglais | MEDLINE | ID: mdl-34461176

RÉSUMÉ

BACKGROUND: Gaseous by-products generated by surgical devices - collectively referred to as 'surgical smoke' - present the hazard of transmitting infective viruses from patients to surgical teams. However, insufficient evidence exists to evaluate and mitigate the risks of SARS-CoV-2 transmission via surgical smoke. AIM: To demonstrate the existence and infectivity of human coronavirus RNA in surgical smoke using a model experiment and to evaluate the possibility of lowering transmission risk by filtration through a surgical mask. METHODS: Pelleted HeLa-ACE2-TMPRSS2 cells infected with human coronavirus were incised by electric scalpel and ultrasonic scalpel, separately. A vacuum system was used to obtain surgical smoke in the form of hydrosol. Reverse transcription-quantitative polymerase chain reaction was used to analyse samples for the presence of viral RNA, and infectivity was determined through plaque assay. Furthermore, a surgical mask was placed centrally in the vacuum line to evaluate its ability to filter viral RNA present in the surgical smoke. FINDINGS: In this model, 1/106 to 1/105 of the viral RNA contained in the incision target was detected in the collected surgical smoke. The virus present in the smoke was unable to induce plaque formation in cultured cells. In addition, filtration of surgical smoke through a surgical mask effectively reduced the amount of viral RNA by at least 99.80%. CONCLUSION: This study demonstrated that surgical smoke may carry human coronavirus, though viral infectivity was considerably reduced. In clinical settings, surgical mask filtration should provide sufficient additional protection against potential coronavirus, including SARS-CoV-2, infection facilitated by surgical smoke.


Sujet(s)
COVID-19 , Fumée , Humains , Masques , ARN viral/génétique , SARS-CoV-2 , Fumée/effets indésirables
3.
J Pediatr Hematol Oncol ; 43(3): 104-111, 2021 04 01.
Article de Anglais | MEDLINE | ID: mdl-33560086

RÉSUMÉ

INTRODUCTION: Sickle cell disease (SCD) is the most common abnormal genetic blood disease that affects ∼100,000 Americans. Approximately 20% to 37% of children with sickle cell anemia have silent cerebral infarcts by the age of 14 years old. Neurocognitive deficits are identified in infants and preschool children with SCD. The purpose of this systematic literature review is to provide a comprehensive understanding of the prevalence, severity, and the associated risk factors for neurodevelopmental delays (NDDs) in children with SCD 5 years of age and younger. METHODS: Systematic search of 6 databases identified 2467 potentially relevant publications and 8 were identified through a manual search. Only 24 articles met the inclusion criteria. RESULTS: We identified an increased prevalence of NDDs (cognitive, motor, or both). Children experienced deficits with language, attention and behavior, executive functioning, school readiness and/or academic performance, and motor skills (fine and gross motor functioning). Risk factors include silent cerebral infarcts and strokes, SCD genotype (HbSS>HbSC), other biologic, and social factors. CONCLUSION: NDDs are common in children ages 0 to 5 years old with SCD. There is an opportunity to improve adherence to national guideline recommendations and early detection practices by pediatricians, hematologists, and other health care providers.


Sujet(s)
Drépanocytose/complications , Développement de l'enfant , Performance scolaire , Attention , Enfant d'âge préscolaire , Cognition , Dysfonctionnement cognitif/étiologie , Incapacités de développement/étiologie , Humains , Nourrisson , Aptitudes motrices , Troubles du développement neurologique/étiologie
4.
Radiat Prot Dosimetry ; 184(3-4): 294-297, 2019 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-31330016

RÉSUMÉ

This paper describes our trial experience of the use of high radiation area for radiation education. We used environmental samples collected from the high radiation area in Fukushima prefecture and India, for the practice of radiation measurement and health risk assessment in Nagasaki University Medical School. We also carried out the field monitoring seminar for students in the existing exposure areas in Tottori prefecture and the Yamakiya observatory in Fukushima. Although the evaluation of educational effectiveness is still underway, both types of education appeared attractive for the students mostly due to the exposure from natural environment in our real life which was not achieved by using an artificial radiation source in a classroom.


Sujet(s)
Rayonnement naturel , Accident nucléaire de Fukushima , Contrôle des radiations/méthodes , Radiobiologie/enseignement et éducation , Appréciation des risques/méthodes , Polluants radioactifs du sol/analyse , Surveillance de l'environnement , Humains , Inde , Japon , Centrales nucléaires
5.
Adv Emerg Nurs J ; 41(1): 86-97, 2019.
Article de Anglais | MEDLINE | ID: mdl-30702538

RÉSUMÉ

Treatment of vaso-occlusive episodes (VOEs) is the most common reason for emergency department (ED) treatment of sickle cell disease (SCD). We (1) compared perceptions of the usability and ability to manage VOE pain between ED nurses and other ED provider types, ED sites, and VOE protocols (individualized vs. weight-based), and (2) identified ED nurse and other provider protocol suggestions. A secondary analysis of provider survey data collected immediately after caring for a patient enrolled in a randomized controlled trial comparing weight-based versus individualized opioid dosing for VOE. Research staff asked the ED nurses and other ED providers (nurse practitioners [NPs], physician assistants [PAs], residents, and attending physicians) 5 questions related to the protocol's ease of use and ability to manage pain. There were 236 surveys completed. Attending physicians (n = 15), residents (n = 88), PAs (n = 21), and NPs (n = l) were more satisfied than nurses (n = 111) with the clarity of the analgesic ordering (97.6% vs. 0%, p = 0.0001) and ability to manage the patient's VOE pain (91% vs. 0%, p = 0.0001). When comparing both protocols with the usual ED strategy in their ED to manage VOE, more nurses than other ED providers perceived the study patients' pain management protocol as better (100% vs. 35.2%, p = 0.0001). Other ED providers perceived the individualized versus weight-based protocol as better at managing pain than their usual ED strategy (70.3% vs. 59.5%, p = 0.04). The individualized protocol was perceived as better in managing VOE than the weight-based ED strategy. While physicians were satisfied with the clarity of the protocols, nurses were not. Improved protocol usability is required for widespread ED implementation.


Sujet(s)
Analgésiques morphiniques/usage thérapeutique , Drépanocytose/complications , Drépanocytose/soins infirmiers , Protocoles cliniques , Connaissances, attitudes et pratiques en santé , Gestion de la douleur/méthodes , Poids , Service hospitalier d'urgences , Femelle , Humains , Mâle , Mesure de la douleur , Enquêtes et questionnaires
6.
Oncogene ; 36(12): 1687-1697, 2017 03 23.
Article de Anglais | MEDLINE | ID: mdl-27694899

RÉSUMÉ

The prevalence of human papillomavirus (HPV)-related oropharyngeal cancers has been increasing in developed countries. We recently demonstrated that members of the apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3, A3) family, which are antiviral factors, can induce hypermutation of HPV DNA in vitro. In the present study, we found numerous C-to-T and G-to-A hypermutations in the HPV16 genome in oropharyngeal cancer (OPC) biopsy samples using differential DNA denaturation PCR and next-generation sequencing. A3s were more abundantly expressed in HPV16-positive OPCs than in HPV-negative, as assessed using immunohistochemistry and reverse transcription quantitative PCR. In addition, interferons upregulated A3s in an HPV16-positive OPC cell line. Furthermore, quantitative PCR analysis of HPV DNA suggests that APOBEC3A (A3A) expression is strongly correlated with the integration of HPV DNA. These results suggest that HPV16 infection may upregulate A3A expression, thereby increasing the chance of viral DNA integration. The role of A3A in HPV-induced carcinogenesis is discussed.


Sujet(s)
Cytidine deaminase/métabolisme , Génome viral , Tumeurs de l'oropharynx/étiologie , Tumeurs de l'oropharynx/métabolisme , Papillomaviridae/physiologie , Infections à papillomavirus/complications , Infections à papillomavirus/virologie , Protéines/métabolisme , Lignée cellulaire tumorale , Cytidine deaminase/génétique , Protéines de liaison à l'ADN/génétique , Régulation de l'expression des gènes tumoraux , Humains , Mutation , Protéines des oncogènes viraux/génétique , Papillomaviridae/classification , Papillomaviridae/génétique , Protéines/génétique
7.
J Endocrinol Invest ; 40(3): 257-261, 2017 Mar.
Article de Anglais | MEDLINE | ID: mdl-27664101

RÉSUMÉ

BACKGROUND/AIMS: The natural course of Graves' orbitopathy (GO) has been poorly documented. The aim of this review is to provide current knowledge regarding the natural course of mild GO, trying to address the issue of whether and to what extent it constitutes a chronic remitting or transient disease. METHODS: We systematically searched PubMed for English language publications until August 2016 under the following terms: "Graves' orbitopathy" OR "Graves' ophthalmopathy" OR "thyroid eye disease" AND "natural course" OR "natural history". RESULTS: Few studies have investigated the course of mild orbital disease in patients with GO. Large controlled trials are lacking and data can be extracted mainly from small retrospective and some prospective studies, after excluding patients who had received radioiodine for thyrotoxicosis or surgical treatment for GO. In general, more than half of GO patients may show spontaneous improvement in their clinical features, whereas no safe conclusions can be drawn with regard to complete resolution, with percentages ranging from 6 to 58 %. CONCLUSIONS: The question whether mild GO is a remitting, albeit chronic disease, or even a transient event in the course of Graves' disease, remains currently unanswered.


Sujet(s)
Ophtalmopathie basedowienne/physiopathologie , Maladie chronique , Humains
8.
J Endocrinol Invest ; 39(8): 849-53, 2016 Aug.
Article de Anglais | MEDLINE | ID: mdl-26956000

RÉSUMÉ

Thyroid hormone acts on the oocytes, sperm and embryo during fertilization, implantation and placentation. Both hypothyroidism and hyperthyroidism may influence fertility. However, evidence of the association of hyperthyroidism with infertility is scarce and sometimes conflicting. Thyroid hormone influences human reproduction via a variety of mechanisms at both the central and the peripheral level. Infertility may occur in hyperthyroid men and women, but it is usually reversible upon restoration of euthyroidism. This review aims to summarize the available data on the association of hyperthyroidism and infertility in both men and women and to provide practical suggestions for the management of these patients.


Sujet(s)
Hyperthyroïdie/physiopathologie , Infertilité/prévention et contrôle , Prise en charge de la maladie , Femelle , Humains , Infertilité/thérapie , Mâle
9.
Ann R Coll Surg Engl ; 97(4): e64-6, 2015 May.
Article de Anglais | MEDLINE | ID: mdl-26263956

RÉSUMÉ

Giant parathyroid adenomas constitute a rare clinical entity, particularly in the developed world. We report the case of a 53-year-old woman where the initial ultrasonography significantly underestimated the size of the lesion. The subsequent size and weight of the adenoma (7 cm diameter, 27 g) combined with the severity of the hypercalcaemia raised the suspicion for the presence of a parathyroid carcinoma. This was later disproven by the surgical and histological findings. Giant parathyroid adenomas are encountered infrequently among patients with primary hyperparathyroidism, and appear to have distinct clinical and biochemical features related to specific genomic alterations. Cross-sectional imaging is mandated in the investigation of parathyroid adenomas presenting with severe hypercalcaemia as ultrasonography alone can underestimate their size and extent. This is important since it can impact on preoperative preparation and planning as well as the consent process as a thoracic approach may prove necessary for certain cases.


Sujet(s)
Adénomes , Hyperparathyroïdie primitive/complications , Glandes parathyroïdes , Tumeurs de la parathyroïde , Adénomes/complications , Adénomes/imagerie diagnostique , Adénomes/anatomopathologie , Adénomes/chirurgie , Femelle , Humains , Hypercalcémie , Adulte d'âge moyen , Glandes parathyroïdes/imagerie diagnostique , Glandes parathyroïdes/anatomopathologie , Glandes parathyroïdes/chirurgie , Tumeurs de la parathyroïde/complications , Tumeurs de la parathyroïde/imagerie diagnostique , Tumeurs de la parathyroïde/anatomopathologie , Tumeurs de la parathyroïde/chirurgie , Radiographie
10.
Int J Clin Pract ; 68(7): 857-63, 2014 Jul.
Article de Anglais | MEDLINE | ID: mdl-24548294

RÉSUMÉ

AIMS: Subclinical hypothyroidism (SH) is associated with increased risk for atherosclerosis, mainly attributable to dyslipidaemia and hypercoagulability. However, conflicting data exist regarding the effect of L-thyroxine substitution on these parameters. The purpose of this study was to assess the effect of L-thyroxine therapy on lipidaemic profile, coagulation markers, high-sensitivity C-reactive protein (hsCRP) and glucose homoeostasis in SH patients. METHODS: It was a prospective open-label study. The following parameters were measured before and 6 months after intervention: anthropometric data, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoproteins B (apoB) and A1 (apoA1), lipoprotein (a) [Lp(a)], fasting plasma glucose and insulin, homoeostasis model assessment-insulin resistance (HOMA-IR), hsCRP, antithrombin III (AT-III), protein C (PC), protein S (PS), fibrinogen and homocysteine. RESULTS: Thirty-two patients (30 women) aged 52.1 ± 13.9 years with SH completed the study. Baseline mean TSH levels were 6.79 ± 2.58 mIU/ml. Achievement of euthyroidism significantly reduced systolic blood pressure (BP) in patients with SH (from 135.2 ± 18.5 to 129.7 ± 15.8 mmHg, p = 0.03) and diastolic BP only in those with baseline TSH levels > 7 mIU/ml (from 79.5 ± 9.8 to 72.1 ± 7.3 mmHg, p = 0.03). No significant changes in body weight, TC, LDL-C, HDL-C, TG, apoB, glucose, insulin, HOMA-IR, hsCRP, AT-III, PC, PS, fibrinogen or homocysteine levels were noticed after restoration of euthyroidism, except for a decrease in apoA1 (p = 0.04) and an increase in Lp(a) levels (p = 0.02). CONCLUSIONS: Except for a reduction in systolic and diastolic BP, thyroid substitution therapy does not affect lipidaemic profile, systematic inflammation, glucose homoeostasis or coagulation in patients with SH.


Sujet(s)
Coagulation sanguine/effets des médicaments et des substances chimiques , Glycémie/effets des médicaments et des substances chimiques , Substitution de médicament , Hypothyroïdie/traitement médicamenteux , Inflammation/traitement médicamenteux , Thyroxine/effets des médicaments et des substances chimiques , Adulte , Sujet âgé , Cholestérol/sang , Femelle , Humains , Hypothyroïdie/complications , Lipides/sang , Adulte d'âge moyen , Études prospectives , Thyroxine/pharmacologie , Triglycéride/sang
11.
Exp Clin Endocrinol Diabetes ; 122(1): 15-9, 2014 Jan.
Article de Anglais | MEDLINE | ID: mdl-24464594

RÉSUMÉ

With the advent of modern imaging modalities, endocrine incidentalomas are increasingly being discovered. We aimed to investigate the presence of pituitary incidentalomas (PI) in patients with adrenal incidentalomas (AI), and identify potential metabolic correlates in this cohort. 26 patients (18 females) with AI discovered on abdominal computerized tomography were studied. All patients underwent pituitary magnetic resonance imaging (MRI) and endocrine investigations to evaluate functional adrenal pathology, anterior pituitary hormonal status, insulin-resistance indices and presence of metabolic syndrome. Pituitary MRI revealed a microadenoma and a 4×5 mm cyst in 1 patient respectively, and an empty sella in 4 (2 partial) patients. Overall, 6/26 (23%) patients with an AI had evidence of pituitary imaging pathology but only 8% had a PI; none had any evidence of abnormalities in pituitary function. Subclinical hypercortisolism was the only hyperfunctional status detected in 4 patients with AI but was unrelated to the pituitary findings. No abnormality of insulin secretion and action was found between patients with or without pituitary pathology. In the present study 23% of patients with AI had some alteration in pituitary morphology, and 2 a PI without accompanying pituitary hormonal deficit or metabolic derangement. Further studies are required to address this issue and identify a potential pathogenetic mechanism.


Sujet(s)
Adénomes/complications , Adénomes/épidémiologie , Tumeurs de la surrénale/complications , Tumeurs de la surrénale/épidémiologie , Tumeurs de l'hypophyse/complications , Tumeurs de l'hypophyse/épidémiologie , Sujet âgé , Diabète de type 2/complications , Diabète de type 2/épidémiologie , Femelle , Hyperglycémie provoquée , Humains , Incidence , Résultats fortuits , Mâle , Adulte d'âge moyen
12.
Int J Impot Res ; 26(1): 13-5, 2014 Jan.
Article de Anglais | MEDLINE | ID: mdl-23823216

RÉSUMÉ

To examine the relationship between chronic periodontal disease (CPD) and ED, the interview sheet including the CPD self-checklist (CPD score) and the five-item version of the International Index of Erectile Function (IIEF-5) was distributed to 300 adult men who received a comprehensive dental examination. Statistical analyses were performed by the Spearman's rank correlation coefficient and other methods. Statistical significance was accepted at the level of P<0.05. The interview sheets were collected from 88 men (response rate 29.3%, 50.9±16.6 years old). There was a statistically significant correlation between the CPD score and the presence of ED (P=0.0415). The results in the present study suggest that ED is related to the damage caused by endothelial dysfunction and the systematic inflammatory changes associated with CPD. The present study also suggests that dental health is important as a preventive medicine for ED.


Sujet(s)
Dysfonctionnement érectile/complications , Maladies parodontales/complications , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Endothélium vasculaire/physiopathologie , Dysfonctionnement érectile/physiopathologie , Humains , Mâle , Adulte d'âge moyen , Maladies parodontales/physiopathologie , Facteurs de risque , Indice de gravité de la maladie , Enquêtes et questionnaires , Jeune adulte
13.
Horm Metab Res ; 45(4): 314-8, 2013 Apr.
Article de Anglais | MEDLINE | ID: mdl-23093460

RÉSUMÉ

Acromegaly is characterized by high cardiovascular morbidity and mortality. Oxidative stress and endothelial dysfunction are underlying mechanisms of atherosclerosis.The aim of this study was to evaluate the blood redox status and endothelial function by means of nitric oxide (NO) levels in patients with acromegaly. Total antioxidant capacity (TAC), catalase activity and glutathione concentration (GSH), as measures of antioxidative capacity, total oxidized glutathione (GSSG) and thiobarbituric acid reactive substances (TBARS), as indices of oxidative stress, and NO levels were assessed in 15 patients with acromegaly (age 55.4±10.5 years; 6 males) and 15 age- and sex-matched controls (age 58.4±8.1 years; 7 males). Active disease was present in 12 patients: 11 on current pharmacotherapy and 1 newly diagnosed. Three acromegalics were in remission after successful treatment. Acromegalics as compared with controls had significantly lower levels of catalase activity (8.2±5.8 vs. 51.3±29.1 mmol/ml/min, p<0.001), GSH (0.97±0.54 vs. 1.41±0.35 mmol/l, p=0.006), GSSG (0.27±0.19 vs. 2.04±1.32 mmol/l, p=0.002) and NO levels (6.0±3.1 vs. 43.0±29.8 mmol/l, p<0.001), but higher TBARS (16.3±8.9 vs. 10.1±10.8, nmol/ml, p=0.019). After adjustment for confounders, differences in catalase activity, NO levels and TBARS remained significant (p=0.004, p<0.001 and p=0.025, respectively). No association between IGF-I/GH and oxidative stress markers was noticed, except for a positive correlation between nadir GH and GSSG (r²=0.563, p=0.036). Acromegaly is associated with increased levels of oxidative stress coupled by diminished antioxidant capacity and endothelial dysfunction indicated by the presence of decreased NO levels.


Sujet(s)
Acromégalie/sang , Antioxydants/métabolisme , Endothélium vasculaire/métabolisme , Stress oxydatif , Acromégalie/anatomopathologie , Sujet âgé , Marqueurs biologiques/sang , Catalase/sang , Études transversales , Endothélium vasculaire/anatomopathologie , Femelle , Glutathion/sang , Humains , Mâle , Adulte d'âge moyen , Monoxyde d'azote/sang , Substances réactives à l'acide thiobarbiturique/métabolisme
14.
Neurology ; 78(15): 1171-8, 2012 Apr 10.
Article de Anglais | MEDLINE | ID: mdl-22459680

RÉSUMÉ

OBJECTIVE: To test efficacy and safety of atorvastatin in subjects with clinically isolated syndrome (CIS). METHODS: Subjects with CIS were enrolled in a phase II, double-blind, placebo-controlled, 14-center randomized trial testing 80 mg atorvastatin on clinical and brain MRI activity. Brain MRIs were performed quarterly. The primary endpoint (PEP) was development of ≥ 3 new T2 lesions, or one clinical relapse within 12 months. Subjects meeting the PEP were offered additional weekly interferon ß-1a (IFNß-1a). RESULTS: Due to slow recruitment, enrollment was discontinued after 81 of 152 planned subjects with CIS were randomized and initiated study drug. Median (interquartile range) numbers of T2 and gadolinium-enhancing (Gd) lesions were 15.0 (22.0) and 0.0 (0.0) at baseline. A total of 53.1% of atorvastatin recipients (n = 26/49) met PEP compared to 56.3% of placebo recipients (n = 18/32) (p = 0.82). Eleven atorvastatin subjects (22.4%) and 7 placebo subjects (21.9%) met the PEP by clinical criteria. Proportion of subjects who did not develop new T2 lesions up to month 12 or to starting IFNß-1a was 55.3% in the atorvastatin and 27.6% in the placebo group (p = 0.03). Likelihood of remaining free of new T2 lesions was significantly greater in the atorvastatin group compared with placebo (odds ratio [OR] = 4.34, p = 0.01). Likelihood of remaining free of Gd lesions tended to be higher in the atorvastatin group (OR = 2.72, p = 0.11). Overall, atorvastatin was well tolerated. No clear antagonistic effect of atorvastatin plus IFNß-1a was observed on MRI measures. CONCLUSION: Atorvastatin treatment significantly decreased development of new brain MRI T2 lesion activity, although it did not achieve the composite clinical and imaging PEP. CLASSIFICATION OF EVIDENCE: This study provided Class II evidence that atorvastatin did not reduce the proportion of patients with CIS meeting imaging and clinical criteria for starting immunomodulating therapy after 12 months, compared to placebo. In an analysis of a secondary endpoint (Class III), atorvastatin was associated with a reduced risk for developing new T2 lesions.


Sujet(s)
Anticholestérolémiants/usage thérapeutique , Encéphale/effets des médicaments et des substances chimiques , Encéphale/anatomopathologie , Acides heptanoïques/usage thérapeutique , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Imagerie par résonance magnétique , Pyrroles/usage thérapeutique , Adulte , Anticholestérolémiants/administration et posologie , Anticholestérolémiants/effets indésirables , Atorvastatine , Canada , , Produits de contraste , Méthode en double aveugle , Femelle , Gadolinium , Acides heptanoïques/administration et posologie , Acides heptanoïques/effets indésirables , Humains , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/administration et posologie , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/effets indésirables , Interféron bêta-1a , Interféron bêta/usage thérapeutique , Imagerie par résonance magnétique/méthodes , Mâle , Adulte d'âge moyen , Odds ratio , Pyrroles/administration et posologie , Pyrroles/effets indésirables , Plan de recherche , Syndrome , Résultat thérapeutique , États-Unis
15.
J Phys Chem Lett ; 3(18): 2659-64, 2012 Sep 20.
Article de Anglais | MEDLINE | ID: mdl-26295888

RÉSUMÉ

Fucoxanthin-chlorophyll-a/c protein (FCP) complexes from brown algae Cladosiphon okamuranus TOKIDA (Okinawa Mozuku in Japanese) contain the only species of carbonyl carotenoid, fucoxanthin, which exhibits spectral characteristics attributed to an intramolecular charge-transfer (ICT) property that arises in polar environments due to the presence of the carbonyl group in its polyene backbone. Here, we investigated the role of the ICT property of fucoxanthin in ultrafast energy transfer to chlorophyll-a/c in brown algal photosynthesis using femtosecond pump-probe spectroscopic measurements. The observed excited-state dynamics show that the ICT character of fucoxanthin in FCP extends its absorption band to longer wavelengths and enhances its electronic interaction with chlorophyll-a molecules, leading to efficient energy transfer from fucoxanthin to chlorophyll-a.

16.
Osteoporos Int ; 23(9): 2387-91, 2012 Sep.
Article de Anglais | MEDLINE | ID: mdl-22120908

RÉSUMÉ

De novo autoimmune hepatitis (AIH) is a rare graft dysfunction occurring in patients having undergone liver transplantation (LT) for causes other than AIH. We describe for the first time a case of de novo AIH associated with the administration of parathyroid hormone 1-34 [PTH(1-34)] and PTH(1-84) for severe osteoporosis. A 61-year-old woman was referred to our metabolic bone clinic due to severe osteoporosis, 3 years after LT for primary biliary cirrhosis. Initial treatment with PTH(1-34) led to asymptomatic hypertransaminasemia (two-fold the upper limit of normal), which normalized after drug discontinuation. A new flare of transaminases (three-fold the upper limit of normal) along with elevated alkaline phosphatase was observed after administration of PTH(1-84), which did not resolve after PTH(1-84) withdrawal. Subsequently, after exclusion of common causes of liver enzyme elevation, a liver biopsy was performed. Histological findings showed de novo AIH, which responded rapidly to treatment with methylprednisolone.


Sujet(s)
Hépatite auto-immune/étiologie , Ostéoporose post-ménopausique/traitement médicamenteux , Hormone parathyroïdienne/effets indésirables , Complications postopératoires/induit chimiquement , Marqueurs biologiques/sang , Femelle , Glucocorticoïdes/usage thérapeutique , Hépatite auto-immune/traitement médicamenteux , Humains , Cirrhose biliaire/chirurgie , Transplantation hépatique , Méthylprednisolone/usage thérapeutique , Adulte d'âge moyen
17.
Oral Dis ; 17(7): 712-9, 2011 Oct.
Article de Anglais | MEDLINE | ID: mdl-21771211

RÉSUMÉ

OBJECTIVE: Mechanical stress is known to be an important factor in the regulation of bone remodeling, and mandibular bone is continuously exposed to mechanical stressors such as occlusal force. Therefore, in this study, we investigated the effects of mechanical stress approaching occlusal force, to which mandible-derived osteoblasts (MDOB) are exposed, on cytokine expression and production using an original hydrostatic pressure apparatus. MATERIALS AND METHODS: The levels of cytokine in MDOB were examined by real-time RT-PCR, ELISA, and western blotting. In addition, mitogen-activated protein kinase inhibitor for ERK1/2, JNK, and p-38 pathways was used to identify the signal transduction pathway. RESULTS: Hydrostatic pressure increased the expression of IL-6 and TNF-α mRNA in a magnitude- and time-dependent manner and also enhanced IL-6 and TNF-α protein production. Furthermore, hydrostatic pressure changed the RANKL/OPG ratio in favor of RANKL for both mRNA and protein levels. Specific inhibitor of p-38 pathway but not that of the ERK1/2 and JNK pathways suppressed the up-regulation of RANKL production induced by hydrostatic pressure loading. CONCLUSION: These results suggest that MDOB play a role in cytokine production in response to mechanical stress and that occlusal force may support the maintenance of mandible bone homeostasis by activating bone remodeling through osteoclastogenesis.


Sujet(s)
Cytokines/biosynthèse , Mandibule/cytologie , Ostéoblastes/métabolisme , Phosphatase alcaline/analyse , Animaux , Phénomènes biomécaniques , Force occlusale , Technique de Western , Remodelage osseux/physiologie , Cellules cultivées , Test ELISA , Extracellular Signal-Regulated MAP Kinases/antagonistes et inhibiteurs , Pression hydrostatique , Interleukine-6/biosynthèse , MAP Kinase Kinase 4/antagonistes et inhibiteurs , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Mâle , Mandibule/métabolisme , Souris , Souris de lignée C57BL , Lignées consanguines de souris , Ostéoprotégérine/biosynthèse , Ligand de RANK/biosynthèse , Réaction de polymérisation en chaine en temps réel , RT-PCR , Contrainte mécanique , Facteur de nécrose tumorale alpha/biosynthèse , p38 Mitogen-Activated Protein Kinases/antagonistes et inhibiteurs
18.
Int J Clin Pract ; 65(8): 896-902, 2011 Aug.
Article de Anglais | MEDLINE | ID: mdl-21679284

RÉSUMÉ

OBJECTIVE: Analysis of patients with acromegaly followed-up at a single centre, focusing on baseline characteristics, morbidity and efficacy of treatment. DESIGN AND METHODS: Retrospective review of electronic medical records of acromegalics from 1987 to 2009. RESULTS: One hundred and fifteen patients (45 men), aged 47 ± 14 years, with a mean follow-up of 8.8 ± 0.8 years were studied. Twenty-five per cent had micro- and 75% macroadenomas. Forty-three per cent presented with visual field defects, 49% had hypertension, 25% diabetes mellitus and 35% dyslipidaemia. At follow-up, 50% had myocardial hypertrophy, 55% colon polypodiasis, 74% nodular thyroid disease and 18% adrenal masses. Surgery was performed in 79% (8% twice), followed by conventional radiotherapy in 27%. Fifty-two per cent of the patients achieved remission. Disease control was reported in 65% of microadenomas and 41% of macroadenomas. Remission rates with surgery alone were 41%. Improvement of remission rates was achieved with subsequent treatment with somatostatin analogues (SSA) (53%), or conventional radiotherapy (63%). Nevertheless, pituitary reserve was compromised with the latter. SSA significantly improved outcomes in microadenomas, even as a monotherapy (remission in 89%), in contrast to macroadenomas (0%), although these agents were associated with impaired glucose metabolism and cholelithiasis in half of the patients. CONCLUSIONS: Acromegaly is associated with an increased morbidity. About half of the treated patients achieved remission (2/3 of microadenomas). The best outcomes were reported for the combination of surgery with radiotherapy, in spite of a higher risk of hypopituitarism. SSA led to remission in a significant percentage of microadenomas, but was associated with increased rates of cholelithiasis and impaired glucose homeostasis.


Sujet(s)
Acromégalie/thérapie , Adénomes/métabolisme , Hormone de croissance humaine/métabolisme , Tumeurs de l'hypophyse/métabolisme , Acromégalie/complications , Acromégalie/anatomopathologie , Adénomes/anatomopathologie , Adénomes/thérapie , Adulte , Glycémie/métabolisme , Association thérapeutique , Femelle , Études de suivi , Humains , Facteur de croissance IGF-I/métabolisme , Mâle , Adulte d'âge moyen , Tumeurs de l'hypophyse/anatomopathologie , Tumeurs de l'hypophyse/thérapie , Études rétrospectives , Résultat thérapeutique
19.
Int J Clin Pract ; 65(6): 679-83, 2011 Jun.
Article de Anglais | MEDLINE | ID: mdl-21564441

RÉSUMÉ

AIMS: The impact of statins on glucose metabolism and adipokines remains controversial. We compared the effects of rosuvastatin and atorvastatin on glucose homeostasis, insulin sensitivity (IS), adiponectin and leptin levels as well as systemic inflammation in non-diabetic patients with dyslipidaemia. METHODS: Thirty-six patients were randomly assigned to 10 mg/day of rosuvastatin (n = 18) or 20 mg/day of atorvastatin (n = 18) for 12 weeks. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, triglycerides (TG), fasting plasma glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), quantitative IS check index (QUICKI), adiponectin, leptin and high-sensitivity C-reactive protein (hsCRP) were measured at baseline and after 4 and 12 weeks. RESULTS: Both statins significantly lowered TC, LDL-C, non-HDL-C and TG compared with baseline. Only rosuvastatin caused a significant reduction in insulin and HOMA-IR levels (-35%, p = 0.005 and -33%, p = 0.011 respectively) and a significant increase in QUICKI (+11%, p = 0.003) at 12 weeks. In terms of adipokines and hsCRP, no difference was observed after 4 and 12 weeks of treatment with either statin. CONCLUSIONS: Rosuvastatin compared with atorvastatin resulted in significant improvements in IS indices. No significant changes in adiponectin, leptin or hsCRP levels were observed at 4 and 12 weeks of treatment with either statin.


Sujet(s)
Adipokines/métabolisme , Glycémie/métabolisme , Dyslipidémies/traitement médicamenteux , Fluorobenzènes/usage thérapeutique , Acides heptanoïques/usage thérapeutique , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Pyrimidines/usage thérapeutique , Pyrroles/usage thérapeutique , Sulfonamides/usage thérapeutique , Sujet âgé , Atorvastatine , Cholestérol/métabolisme , Dyslipidémies/sang , Femelle , Humains , Insuline/métabolisme , Adulte d'âge moyen , Études prospectives , Rosuvastatine de calcium , Triglycéride/métabolisme
20.
Clin Radiol ; 66(3): 264-8, 2011 Mar.
Article de Anglais | MEDLINE | ID: mdl-21295206

RÉSUMÉ

AIM: To assess the characteristics of [(18)F]-fluoro-2-deoxy-d-glucose (FDG) uptake in cases of ovarian metastasis using positron-emission tomography/computed tomography (PET/CT). MATERIALS AND METHODS: Twelve patients with 16 ovarian metastases arising from colon cancer (n=6), breast cancer (n=4), gastric cancer (n=3), and pancreatic cancer (n=3) who underwent FDG-PET/CT examination were included in this study. The effect of lesion size and morphological pattern (predominantly solid or cystic) on FDG uptake was evaluated using the quantitative standardized uptake value (SUV). RESULTS: The mean maximum SUV for the 16 lesions was 4.6±2.4 (range 1.8∼9.9). The Pearson correlation coefficient test showed no significant correlation between maximum SUV and lesion size (r=0.21, p=0.42). The maximum SUV of solid (n=5) and cystic (n=11) lesions was 5.5±2.7 and 4.3±2.2, respectively, and the difference was not significant (p=0.43). Breast cancer showed the highest maximum SUV (6.4±3.6), followed by colon cancer (5.3±1.4), gastric cancer (3.3±0.5), and pancreatic cancer (2.2±0.6). CONCLUSION: Ovarian metastases show a variable maximum SUV with mild to intense FDG uptake.


Sujet(s)
Fluorodésoxyglucose F18 , Tumeurs de l'ovaire/imagerie diagnostique , Tumeurs de l'ovaire/secondaire , Tomographie par émission de positons/méthodes , Radiopharmaceutiques , Adulte , Tumeurs du sein , Tumeurs du côlon , Femelle , Fluorodésoxyglucose F18/pharmacocinétique , Humains , Adulte d'âge moyen , Tumeurs du pancréas , Radiopharmaceutiques/pharmacocinétique , Tumeurs de l'estomac
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...